Barbara Haakevfa, Association of Researched based Pharmaceutical Companies, GermanyPublic awareness about new medicines de...
Looking into the futurePatients advocatesPatient organisationsThe general public.How tools and knowledge provided through ...
By 2020 the Patients‘ Academy has…developed and disseminated accessible, well-structured anduser-friendly information and ...
By 2020 the Patients‘ Academy has…created the leading public (internet) library on medicines R&D in 7 (and perhaps more) ...
By 2020 the Patients‘ Academy has…built expert capacity by training patient advocates,and competencies among patients and ...
By 2020 the Patients‘ Academy has…developed: new and innovative concepts that ensure more activeinvolvement of patient ex...
By 2020 the Patients‘ Academy has… reached-out to many patient organisations, academicorganisations, NGOs and pharma comp...
By 2020 the National Platforms are… raising pan-European programme awareness and public interestabout medicines R&D fost...
By 2020 the EUPATI Network is……using the EUPATI‟s digital platforms on Internet & Social Media
By 2020 the EUPATI Network has… …increased public confidence inmedicines R&D,e.g. resulting in improvement on• trial cons...
By 2020 the Patients‘ Academy … is accepted as a trustworthy source of informationon how medicine R&D works has establis...
Today the EUPATI Network is …PatientAdvocacyOrgs(national/int„l)Industry &CROsAcademiaResearchnetworks,& projectsRegulator...
And in 2020 the Network is …
Thank you!
Upcoming SlideShare
Loading in …5
×

EUPATI 2013 Conference: Public awareness about new medicines development in 2020 Bring to life with EUPATI examples

602 views

Published on

EUPATI 2013 Conference: Public awareness about new medicines development in 2020 Bring to life with EUPATI examples, by Barbara Haake, vfa, Association of Researched based Pharmaceutical Companies, Germany

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
602
On SlideShare
0
From Embeds
0
Number of Embeds
265
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

EUPATI 2013 Conference: Public awareness about new medicines development in 2020 Bring to life with EUPATI examples

  1. 1. Barbara Haakevfa, Association of Researched based Pharmaceutical Companies, GermanyPublic awareness about new medicines development in 2020Bring to life with EUPATI examplesThe project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115334, resources of which are composedof financial contribution from the European Unions Seventh Framework Programme (FP7/2007-2013) and EFPIA companies.
  2. 2. Looking into the futurePatients advocatesPatient organisationsThe general public.How tools and knowledge provided through EUPATI could make adifference to
  3. 3. By 2020 the Patients‘ Academy has…developed and disseminated accessible, well-structured anduser-friendly information and education on medicines R&D EUPATI Certificate Training Programmee.g. Academic Modular Certificate Programme EUPATI "Toolbox" with educational tools in a variety of distributable formats: paper-based booklets, leaflets,presentations, eLearning, webinars, videos,YouTube, films and/orcartoons etc. EUPATI Internet Library
  4. 4. By 2020 the Patients‘ Academy has…created the leading public (internet) library on medicines R&D in 7 (and perhaps more) languages under “Creative Commons” license
  5. 5. By 2020 the Patients‘ Academy has…built expert capacity by training patient advocates,and competencies among patients and the public Patient Ambassadors Patient Journalists Patient Facilitators/Trainers Representatives of patient organisations Lay patients and the general public
  6. 6. By 2020 the Patients‘ Academy has…developed: new and innovative concepts that ensure more activeinvolvement of patient experts in medicines R&D, HTA, … guidelines for interaction between stakeholders, ethicalprinciples and best practice procedures best practice guidelines for patient involvement in researchand drug development a road map for the collaboration with highly innovativesectors of industry, including and beyond the pharmaceuticalindustry, and Health Authorities
  7. 7. By 2020 the Patients‘ Academy has… reached-out to many patient organisations, academicorganisations, NGOs and pharma companies who are involved inmedicines R&D organized many conferences, workshops and meetings oninternational and national level been present on many external events created National Liaison Teams (NLTs)with one representative each of apatient organisation, academicinstitution and industry in each ofthe12 countries established EUPATI National Platforms (ENPs) in 12 countries
  8. 8. By 2020 the National Platforms are… raising pan-European programme awareness and public interestabout medicines R&D fostering the contact with national patient organisations collecting educational material in the countries, translating materialin their languages and adapting it to local needs facilitating national dissemination/adaptation of the IT platform identifying training faculty members, organizing face-to-face learningand educational opportunities disseminating information in local media identifying best national pathways to raiseawareness identifying future topics of nationalinterest ensuring the availability of resourcesand the long-term sustainability of thePatients‟ Academy
  9. 9. By 2020 the EUPATI Network is……using the EUPATI‟s digital platforms on Internet & Social Media
  10. 10. By 2020 the EUPATI Network has… …increased public confidence inmedicines R&D,e.g. resulting in improvement on• trial consent & recruitment• generation of meaningful clinicaldata• pace of progress in research… …by providing objective informationand more transparency aboutmedicine R&D processes towardsthe public
  11. 11. By 2020 the Patients‘ Academy … is accepted as a trustworthy source of informationon how medicine R&D works has established effective, transparent and credible partnershipsacross all stakeholders has created exceptional learning experience for researchers inacademia and industry to work with patient organisations in aconstructive and reflective manner is accepted as a role model in other environments has made best use of expertise of R&D professionalsfrom academia and industry has reduced fear, lack of trust and misconceptionamong patients about medicines R&DWith the aim of improving thelives of patients in Europe!
  12. 12. Today the EUPATI Network is …PatientAdvocacyOrgs(national/int„l)Industry &CROsAcademiaResearchnetworks,& projectsRegulatoryauthoritiesPolicymakers(EU &MemberStates)EthicsCom-mitteesJourna-lists(medical,lay press)Health-relatedNGOs
  13. 13. And in 2020 the Network is …
  14. 14. Thank you!

×